First Trust Advisors LP Makes New Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)

First Trust Advisors LP acquired a new position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 63,429 shares of the company's stock, valued at approximately $1,002,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in RDY. Geode Capital Management LLC boosted its stake in shares of Dr. Reddy's Laboratories by 109.3% during the 3rd quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock worth $1,053,000 after acquiring an additional 6,920 shares during the last quarter. GAMMA Investing LLC lifted its position in Dr. Reddy's Laboratories by 369.9% during the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company's stock valued at $107,000 after purchasing an additional 5,352 shares in the last quarter. Nordea Investment Management AB grew its holdings in Dr. Reddy's Laboratories by 441.8% during the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company's stock valued at $1,992,000 after purchasing an additional 102,226 shares during the period. Aprio Wealth Management LLC increased its position in Dr. Reddy's Laboratories by 515.6% in the fourth quarter. Aprio Wealth Management LLC now owns 18,807 shares of the company's stock worth $297,000 after buying an additional 15,752 shares in the last quarter. Finally, Harbour Capital Advisors LLC raised its stake in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Harbour Capital Advisors LLC now owns 25,100 shares of the company's stock worth $388,000 after buying an additional 20,080 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

Dr. Reddy's Laboratories stock opened at $13.51 on Thursday. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The firm has a market capitalization of $11.28 billion, a price-to-earnings ratio of 21.51 and a beta of 0.33. The firm has a 50 day moving average of $13.27 and a 200 day moving average of $14.12. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.